---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056893"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:51:36.524346+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics Q1 2024 revenue $27.2M, net income $9.9M; F351 Phase3 data due early 2025

## Summary
- Revenue $27.2M (+9% YoY); net income $9.9M vs $4.2M; ETUARY sales $26.9M (+10% YoY).
- Cash $29.8M as of March 31, 2024 (from $33.5M at Dec 2023); expects >12 months runway.
- Phase 3 F351 for CHB liver fibrosis on track; topline data expected by early 2025.
- U.S. IND for F351 in NASH fibrosis expected late 2024; Phase 2a trial planned in 2025.
- Acquired nintedanib rights from Jiangsu Wangao to strengthen PRC pulmonary fibrosis franchise.

## SEC filing metadata
- accession: 0000950170-24-056893
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/0000950170-24-056893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/gyre-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056893
- JSON: https://secwatch.observer/filing/0000950170-24-056893.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056893.txt

## Key facts
- Earnings Releases
  GYRE THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: revenue $27.2 million.
  - Period: the three months ended March 31, 2024
  - Revenue: $27.2 million
  - Result: reported results
  source text: of the condensed consolidated financial statements. Financial Results for the Quarter Ended March 31, 2024 • Revenues: For the three months ended March 31, 2024, revenues were $27.2 million as a result of Gyre’s indirect controlling interest in Gyre Pharmaceuticals. For the three months ended March 31, 2023, revenues were $24.9 million. The increase was driven by a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/0000950170-24-056893-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.